One of the biggest challenges standing in the way of cell culture vaccine production is achieving cell line qualification, and standing in the way of this is proving you have scanned for all known and unknown pathogens throughout bio-production.
In April the leading players working to try to achieve this goal are going to be in Washington D.C. discussing their strategies and debating the solutions.
Do you want to know;
- how to effectively integrate technologies with bio-informatic analysis?
- whether this goal ever be achieved with complete accuracy?
- What are the cost implications are, and what impact will they have on the further development of this industry?
- Will one screening method be enough, or will multiple techniques have to be used to yield confidence in the results?
Would you love to hear the thoughts and insights of;
- Dr Richard Schwartz, Chief, Vaccine Production Lab, Vaccine Research Center, National Institutes of Health (Panel Moderator)
- Dr Arifa Khan, Senior Investigator, CBER, US FDA
- Dr Mark Galinski, Senior Director of Analytical Biochemistry in Vaccine Development, MedImmune
- Dr Paul Duncan, Senior Investigator, Vaccine Bioprocess R&D, Merck & Co.
- Dr Crystal Jaing, Group Leader, Applied Genomics, Physical Life Sciences Directorate, Lawrence Livermore National Laboratory
Then join us at the World Vaccine Cell Culture Congress, taking place in Washington D.C. on the 11-12 April 2012
REGISTER TODAY to secure your place in the debate!